Compare Novavax Inc (NVAX) vs Prospect Capital Corporation (PSEC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs Prospect Capital Corporation — how do they compare? Novavax Inc trades at $9.9 (market cap $1.68B), while Prospect Capital Corporation trades at $2.22 (market cap $1.13B). The key difference: Novavax Inc is the larger of the two by market cap, and Prospect Capital Corporation pays a 19.09% dividend while Novavax Inc pays none. Which is the better fit depends on your goals.
| NVAX | PSEC | |
|---|---|---|
Market Cap | $1.68B | $1.13B |
Sector | Health | Financials |
52-Week High | $11.19 | $3.05 |
52-Week Low | $6.22 | $2.11 |
Enterprise Value | $1.26B | — |
Dividend Yield | — | 19.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $10.19, showing modest daily movement with a -0.29% decline. The stock maintains a bullish technical signal with strong moving average support. Recent quarterly earnings have consistently beaten expectations, though the company faces profitability challenges with a -59.87% net income margin. Positive developments include regulatory approvals for its updated COVID-19 vaccine and progress in the Sanofi partnership, driving investor optimism.
The outlook remains mixed with strong analyst support (74% buy ratings) but significant financial risks. Investment opportunity lies in the company's partnership strategy and Matrix-M adjuvant platform, while risks include cash flow challenges and competitive vaccine market pressures. The stock's low P/E ratio of 3.14 suggests potential undervaluation if operational improvements continue.
Prospect Capital (PSEC) trades at $2.19, down 1.79% recently, with a bearish technical signal and deep discount to book value (P/B 0.39). The company reported negative revenue and net income for 2025, though quarterly EPS has beaten estimates. It maintains a high dividend yield, paying $0.04 monthly, but faces net cash outflow and portfolio contraction concerns highlighted in recent news.
Outlook remains cautious due to financial deterioration and NAV erosion risks, offset by high yield and valuation discount. Analyst consensus is mixed with 25% buy ratings, reflecting divided opinion on recovery potential versus ongoing operational challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About Prospect Capital Corporation
Prospect Capital Corp is a closed-end investment company based in the United States. Its investment objective is to generate both current income and long-term capital appreciation through debt and equity investments. The company invests primarily in senior and subordinated debt and equity of private companies for acquisitions, divestitures, growth, development, recapitalizations, and other purposes. It makes investments, including lending in private equity, sponsored transactions, directly to companies, investments in structured credit, real estate, and syndicated debt.
Read more on PSEC →
